#phase-1c

#phase-1c

Resident Mike Morris expressed that the project will burden the community, citing existing congestion on local roads. He stated, 'This is the wrong neighborhood for such a massive project.'

Incyte tops this list due to its rare combination of commercial scale, cash generation, and pipeline depth. The company posted FY2025 revenue of $5.14 billion, up 21.2% YoY, anchored by Jakafi generating $828.2 million in Q4 2025 alone (+7% YoY) and Opzelura delivering $207.3 million (+28% YoY). With $3.58 billion in cash and 14 pivotal clinical trials underway, Incyte offers an acquirer immediate revenue, margin expansion potential, and a deep oncology pipeline spanning KRASG12D, CDK2 inhibition, and mutCALR.

Lilly's fourth quarter revenue reached $19.29 billion, up 42.6% year-over-year, powered almost entirely by two products. Mounjaro generated $7.41 billion, up 110%, while Zepbound added $4.26 billion, up 123%.

The funds raised through Visionaries of the Year are used for research to advance lifesaving therapies like immunotherapy, genomics and personalized medicine, which are saving lives today.

Keytruda, first approved in 2014, belongs to a class of immunotherapy drugs that enable the immune system to attack cancer cells, extending survival for millions and transforming fatal diagnoses into manageable conditions.

The study published in the Lancet analyzed data from 381 patients with platinum-resistant ovarian cancer, revealing a 35% reduction in the risk of death among those treated with relacorilant compared to usual care.

On that sunny March morning, in a small health center in Lobamba, a rural area of Eswatini, this 32-year-old sex worker has just become one of the first people in the world to receive lenacapavir, a drug that, administered twice a year, offers nearly 100% protection against HIV.

The INLIGHT interim readout reported a 14.3% placebo-adjusted reduction in visceral fat six months after a single dose, alongside preservation of lean muscle mass - a differentiated profile compared to GLP-1 therapies that often reduce muscle alongside fat.

New findings on cancer survival rates offer hope for the more than 2 million Americans diagnosed each year. Seven out of 10 Americans diagnosed with cancer now survive five years or more, according to the American Cancer Society, a 7 percent increase since the mid-1990s, when the rate stood at 63 percent. The survival rate data - from patients diagnosed with cancer between 2015 and 2021 - showed, significantly, that those with high-mortality cancers and advanced diagnoses had the largest gains.

Emma Dyer remembers the moment she clicked "buy now" on a set of weightloss jabs she found online. She had no medical consultation, no ID checks, and no questions about her history of anorexia and bulimia. "It was just so easy - too easy," she says. "They never asked for my medical history or what medication I was taking. It was like buying groceries."

For years, scientists have viewed cancer as a localized glitch in which cells refuse to stop dividing. But a new study suggests that, in certain organs, tumors actively communicate with the brain to trick it into protecting them. Scientists have long known that nerves grow into some tumors and that tumors containing lots of nerves usually lead to a worse prognosis.

A report last year found unnecessary surgeries were carried out, cancers were missed and poor standards of care were delivered at the University Hospital of North Durham and Darlington Memorial Hospital. CDDTF said it wanted to support the patients it had let down, including by offering access to psychological support, and to ensure they knew how to make a claim or raise concerns with police.

X4 Pharmaceuticals drew a fresh initiation from Guggenheim, which assigned a Buy rating and $12 price target, framing the company as a "differentiated hematology play" with significant upside in the next 18 months. The firm's thesis centers on mavorixafor, a potential first-in-class oral CXCR4 antagonist already approved for WHIM syndrome and currently in Phase 3 development for primary chronic neutropenia.

The cancer was fastacting, and if I'd left it even six months, the outcome could have been much worse,

As for side effects, the companies reported that little had changed from previous analyses; adverse events were similar between the two groups. The top side effects linked to the vaccine were fatigue, injection site pain, and chills. The results "highlight the potential of a prolonged benefit" of the vaccine combined with Keytruda in patients with high-risk melanoma," Kyle Holen, a senior vice president at Moderna, said. They also "illustrate mRNA's potential in cancer care," he said, noting that the company has eight more Phase 2 and Phase 3 trials going for mRNA vaccines against a variety of other cancers, including lung, bladder, and kidney cancers.

CITYWIDE - NYU LANGONE HEALTH HAS APPOINTED DR. ANIRBAN MAITRA, a leader in gastrointestinal oncology, as the new director of its Laura and Isaac Perlmutter Cancer Center, an NCI-designated Comprehensive Cancer Center. Dr. Maitra is a preeminent physician-scientist whose work has widely influenced the field of pancreatic cancer research. As the inaugural scientific director of the Pancreatic Cancer Research Center at the University of Texas MD Anderson Cancer Center in Houston, Dr. Maitra focused his work on early detection and biomarker development, considered two key avenues for effective cancer treatments.